Glyceryl Trinitrate Hospira Uk

Glyceryl Trinitrate Hospira Uk is an injectable solution that contains the active ingredient glyceryl trinitrate. It is supplied as a sterile liquid for intravenous use and is marketed in the European Union by prescription only. Strength is not specified on the label, and the product belongs to the organic nitrate class used as an anti‑anginal agent. It should be stored under controlled temperature conditions during transport.

Glyceryl trinitrate injectable solution is indicated for several acute cardiovascular conditions where rapid vasodilation is required to relieve myocardial oxygen demand and improve hemodynamics.

- Acute angina pectoris – relief of chest pain unresponsive to oral nitrates. - Acute heart failure, particularly pulmonary edema – reduction of preload and afterload. - Hypertensive emergencies – rapid blood pressure lowering when other agents are unsuitable. - Controlled hypotension during surgical procedures – to provide a bloodless field. - Management of myocardial ischemia during cardiac catheterisation or angioplasty – to prevent spasm and improve flow.

Adverse reactions to glyceryl trinitrate injection are primarily linked to its nitric‑oxide mediated vasodilation; they can be mild and transient or, in rare cases, clinically significant.

Common: - Headache – throbbing pain often occurring shortly after infusion. - Flushing – warm sensation and redness of the skin. - Mild hypotension – drop in blood pressure that usually resolves with dose adjustment. - Reflex tachycardia – compensatory increase in heart rate. - Nausea or vomiting – gastrointestinal discomfort without severe consequences.

Serious: - Severe hypotension – marked blood pressure fall that may require emergency intervention. - Methemoglobinemia – elevated methemoglobin levels causing cyanosis and reduced oxygen delivery. - Cardiac ischemia worsening – paradoxical increase in myocardial oxygen demand leading to chest pain.

When using glyceryl trinitrate injection, clinicians should observe several precautions to minimise risks and ensure safe administration.

- Continuously monitor blood pressure and heart rate throughout the infusion. - Avoid use in patients with severe anemia or significant hypoxia. - Exercise caution in individuals with increased intracranial pressure. - Do not combine with phosphodiesterase‑5 inhibitors due to risk of profound hypotension. - Adjust dosing in patients with recent myocardial infarction or unstable coronary disease. - Consider hepatic impairment when determining infusion rates. - Store the product according to manufacturer guidelines to maintain stability.

Glyceryl trinitrate can interact with other medications that affect vascular tone or nitric‑oxide pathways.

Avoid: - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) – risk of profound hypotension. - Other potent vasodilators (e.g., nitroprusside, hydralazine) – additive blood pressure lowering.

Use with caution: - Beta‑blockers – may blunt reflex tachycardia but still require monitoring. - Calcium channel blockers – combined effect on blood pressure. - Antihypertensive agents (ACE inhibitors, ARBs) – cumulative hypotensive effect. - General anaesthetics – may enhance vasodilation during surgery.